MultiCare Health System

Pulmonary Embolism & Deep Vein Thrombosis Study - Daiichi

Title: DUI 176b-D-U305- A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfin in subjects with symptomatic deep-vein thrombosis and/or pulmonary embolism.

Purpose: This study compares Warfarin to Edoxaban in the treatment of symptomatic DVT and PE. Patients are treated with either Edoxaban or standard therapy with LMW transitioned to Warfarin.

Who Can Participate?

Diagnosis or Condition: Newly diagnosed or recurrent PE-Pulmonary Embolus andor DVT-deep vein thrombosis

Age: 18 yrs or older

Sex: Males and Females

Visits: Minimum of 3 months – Maximum of 12 months

Stipend: You will be compensated for your time and travel

Principal Investigator: David Chen, MD

Study Coordinator: Carole Burton, 253.403.7251 or Wendy Carnahan, 253.403.7249

For more information, contact the Study Coordinator and reference Daiichi study

For more information about this study, click here.

Share With Friends